Cymabay Therapeutics (CBAY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 03-2020 | 12-2019 | 09-2019 | 06-2019 | 03-2019 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -13,088 | -102,808 | -73,395 | -47,113 | -23,075 |
| Depreciation Amortization | -52 | -1,665 | -1,487 | -1,046 | -406 |
| Accounts payable and accrued liabilities | -1,290 | N/A | -479 | 909 | 437 |
| Other Working Capital | -3,566 | -3,906 | -2,376 | -3,107 | -1,255 |
| Other Operating Activity | 3,288 | 10,468 | 7,962 | 3,709 | 1,905 |
| Operating Cash Flow | $-14,708 | $-97,911 | $-69,775 | $-46,648 | $-22,394 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 46,633 | -34,032 | -43,319 | -81,847 | -8,866 |
| PPE Investments | N/A | -315 | -289 | -269 | -178 |
| Investing Cash Flow | $46,633 | $-34,347 | $-43,608 | $-82,116 | $-9,044 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | N/A | 108,132 | 107,850 | 107,850 | 108,017 |
| Financing Cash Flow | $N/A | $108,132 | $107,850 | $107,850 | $108,017 |
| Beginning Cash Position | 24,869 | 48,995 | 48,995 | 48,995 | 48,995 |
| End Cash Position | 56,794 | 24,869 | 43,462 | 28,081 | 125,574 |
| Net Cash Flow | $31,925 | $-24,126 | $-5,533 | $-20,914 | $76,579 |
| Free Cash Flow | |||||
| Operating Cash Flow | -14,708 | -97,911 | -69,775 | -46,648 | -22,394 |
| Capital Expenditure | 0 | -315 | -289 | -269 | -178 |
| Free Cash Flow | -14,708 | -98,226 | -70,064 | -46,917 | -22,572 |